Boston — Form Health has begun prescribing weight-loss medications through the new Medicare GLP-1 Bridge Program, which expands access to certain GLP-1 drugs for eligible Medicare Part D beneficiaries with obesity.
The digital obesity and cardiometabolic care provider said it has long accepted Medicare and has the clinical infrastructure needed to help eligible patients obtain GLP-1 medications as part of comprehensive, physician-led obesity care.
Form also coordinates with pharmaceutical manufacturer programs, allowing eligible patients to receive prescribing, clinical management and other support through a single obesity care provider.
“The Medicare GLP-1 Bridge Program represents an important step toward expanding access to evidence-based obesity treatment for millions of Americans,” said Evan Richardson, founder and CEO of Form Health. “Because we’ve long cared for Medicare patients and are the only company to partner with both pharmaceutical leaders in this space, we’re able to help beneficiaries understand their eligibility, navigate this new pathway, and receive comprehensive care that goes well beyond a prescription. Our goal is to make access as seamless as possible while delivering the clinical support patients need to achieve lasting health outcomes.”
The Centers for Medicare & Medicaid Services demonstration program runs from July 1, 2026, through Dec. 31, 2027. It operates outside the standard Medicare Part D benefit and requires participating clinicians to determine eligibility, submit prior authorization requests through a centralized processor, prescribe treatment when appropriate and provide ongoing clinical management.
Form said its American Board of Obesity Medicine-certified physicians and multidisciplinary care teams combine medication, when appropriate, with nutrition guidance, physical activity and behavioral support rather than treating GLP-1 drugs as a standalone solution.
The company said it is available to help eligible Medicare beneficiaries navigate the new coverage pathway as demand for obesity treatment grows.
